The road to health technology assessment has taken different paths in the APAC region.
Since 2017, China has made substantial changes to the market access process, including the introduction of price negotiation and the use of health economics to evaluate the value of new medicines. With HTA involvement in the reimbursement process, there are new challenges for pharmaceutical companies in gathering local data and using health economic modeling to provide economic value evidence. Using the right set of pricing and market access strategies will help manufacturers in achieving inclusion in the Chinese National Reimbursement Drug List (NRDL).
In 2019, Japan’s Ministry of Health, Labour and Welfare (MHLW) launched a formal HTA process for new drugs following a two-year pilot cost-effectiveness assessment (CEA) process for existing drugs and medical devices with the highest premiums. Decisions arising from the pilot were the use of CEA solely for price adjustment (not reimbursement) as well as factors for selecting products for appraisal.
Join us for insights and key lessons learned when engaging with the developing HTA processes in China and Japan. Learn the process and challenges to get on the NRDL in China or with undergoing price adjustment review with the MHLW in Japan, including:
- Current HTA submission guidelines
- Recent changes and challenges in market access process
- Use of health economic modeling to generate value evidence package
- Lessons learned impacting a positive process
On-Demand Webinar Archive
To access the archived recording of this webinar, visit our webinar channel and complete a one time only form. This will give you access to our entire library of archived webinars.Access Webinar Archive
This webinar is intended for professionals from pharmaceutical, biotech, and medical device companies involved in:
- Health economics & outcomes research (HEOR)
- Market access
- Medical affairs
- Regulatory affairs
- Pharmacovigilance and risk management
Lead Consultant, Global HTA, Health Economics, Reimbursement and Outcomes, ICON plc
Xuan Wang has over 10 years’ experience in health economics and outcomes research and has led numerous evidence generation activities to demonstrate product value. She has extensive experience in literature reviews, evidence synthesis and health economic modelling. Prior to joining ICON, Xuan worked as a physician at Beijing Anzhen Hospital, Capital Medical University, China, and has four solid years of practice experience in clinical medicine. Xuan also holds a MSc in Health Economics and Health Promotion from Karolinska Institutet, Sweden.
Senior Consultant, Global HTA, Health Economics, Reimbursement and Outcomes, ICON plc
Kerigo Ndirangu has over 6 years’ experience in health economics and outcomes research demonstrating the economic value of pharmaceutical products, in both the early and late stages of product development. At ICON, she is responsible for developing economic models in diverse disease areas and populations for HTA submissions globally. Prior to joining ICON, Kerigo completed an MPH in Epidemiology at Boston University.